Irbesartan Sandoz (Irbesartan)

Irbesartan works by selectively blocking the angiotensin II type 1 (AT1) receptors on blood vessels and adrenal glands. This inhibition prevents angiotensin II‑induced vasoconstriction and aldosterone secretion, leading to relaxed blood vessels, reduced sodium and water retention, and consequently lower arterial pressure.

The appropriate dose is individualized by the prescribing healthcare professional based on the patient’s blood pressure, kidney function, concomitant medications, and overall clinical condition. No fixed regimen can be stated here; the prescriber decides the strength and frequency.

Irbesartan is classified as pregnancy category D, indicating evidence of risk to the fetus. It should be avoided in pregnancy unless the potential benefit justifies the risk. Limited data are available for breastfeeding, and the drug is generally not recommended for nursing mothers.

To place an order, submit an enquiry on the Irbesartan Sandoz product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, shipping details and any necessary import documentation.

Compared with ACE inhibitors, Irbesartan provides similar blood‑pressure reduction but carries a lower risk of cough and angioedema. Unlike calcium‑channel blockers, it directly blocks the renin‑angiotensin system, offering renal‑protective benefits in diabetic patients. Its once‑daily dosing and tolerability make it a convenient option for many patients.

Irbesartan Sandoz tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Do not store in humid environments or expose the product to excessive heat, as stability may be compromised.

Irbesartan Sandoz is taken orally, usually as a whole tablet with or without food. The exact timing and frequency are determined by the prescribing clinician, who may advise taking the dose at the same time each day to maintain consistent blood‑pressure control.

The most serious adverse events include angioedema, which can affect the face, lips, tongue or airway; severe hypotension leading to dizziness or fainting; acute kidney injury, especially in patients with pre‑existing renal impairment; hyperkalemia, which may cause cardiac arrhythmias; and rare cases of hepatic injury.

Irbesartan should be avoided in patients with known hypersensitivity to irbesartan or any component of the formulation, in those with severe hepatic impairment, and in pregnant women unless the benefit outweighs the risk. Caution is also advised for individuals with bilateral renal artery stenosis or severe kidney disease.